Citadel Advisors
PRVA icon

Citadel Advisors’s Privia Health PRVA Stock Holding History

Citadel Advisors’s Portfolio PRVA Stock Details PRVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-21,300
Closed -$490K – 13811
2025
Q2 		$490K Buy
21,300
+3,500
+20% +$81K ﹤0.01% 8678
2025
Q1 		$400K Buy
17,800
+4,600
+35% +$107K ﹤0.01% 8971
2024
Q4 		$258K Buy
13,200
+3,600
+38% +$71.3K ﹤0.01% 9962
2024
Q3 		$175K Sell
9,600
-2,000
-17% -$38.2K ﹤0.01% 10344
2024
Q2 		$202K Sell
11,600
-27,000
-70% -$478K ﹤0.01% 9924
2024
Q1 		$756K Buy
38,600
+24,800
+180% +$524K ﹤0.01% 7505
2023
Q4 		$318K Sell
13,800
-4,800
-26% -$107K ﹤0.01% 9050
2023
Q3 		$428K Sell
18,600
-1,600
-8% -$40.7K ﹤0.01% 8411
2023
Q2 		$527K Buy
20,200
+2,000
+11% +$52.8K ﹤0.01% 7827
2023
Q1 		$503K Buy
18,200
+10,100
+125% +$267K ﹤0.01% 8296
2022
Q4 		$184K Buy
8,100
+2,100
+35% +$58.5K ﹤0.01% 10275
2022
Q3 		$204K Buy
+6,000
New +$222K ﹤0.01% 10366
2022
Q2 		– Sell
-31,400
Closed -$839K – 13840
2022
Q1 		$839K Buy
31,400
+18,000
+134% +$425K ﹤0.01% 8112
2021
Q4 		$347K Buy
+13,400
New +$334K ﹤0.01% 10596

Other funds holding PRVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCP
Durable Capital Partners Bethesda, Maryland $9.71B AUM 26.27% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
RF
Rubicon Founders Nashville, Tennessee $138M AUM 61.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.08B AUM 12.07% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Citadel Advisors's PRVA Position: Q1 2026 in Review

Citadel Advisors reduced its Privia Health (PRVA) stake by 34% in Q1 2026, selling an estimated $5.67M and leaving 490,413 shares worth $10.1M. The position accounts for ﹤0.01% of the portfolio, ranked #3240.

Citadel Advisors first reported a position in PRVA in Q2 2021 and has held it in 18 quarters since. The position peaked at $32.3M in Q3 2022. 293 funds tracked by Wall St. Rank hold PRVA as of Q1 2026.

  • Citadel Advisors held 490,413 shares of Privia Health worth $10.1M as of Q1 2026.
  • Citadel Advisors sold 251,769 Privia Health shares in Q1 2026, an estimated $5.67M.
  • Privia Health made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3240 holding.
  • Citadel Advisors first reported a position in Privia Health in Q2 2021 and has held it in 18 quarters since.
  • Citadel Advisors's Privia Health position peaked at $32.3M in Q3 2022.
  • 293 funds tracked by Wall St. Rank held Privia Health as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.